Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK.
Gough SC, Belda-Iniesta C, Poole C, Weber M, Russell-Jones D, Hansen BF, Mannucci E, Tuomilehto J. Gough SC, et al. Adv Ther. 2011 Sep;28 Suppl 5:1-18. doi: 10.1007/s12325-011-0047-8. Epub 2011 Aug 19. Adv Ther. 2011. PMID: 21863297
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R; NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators. Zinman B, et al. Lancet Diabetes Endocrinol. 2013 Oct;1(2):123-31. doi: 10.1016/S2213-8587(13)70013-5. Epub 2013 Jul 9. Lancet Diabetes Endocrinol. 2013. PMID: 24622318 Clinical Trial.
Insulin X10 revisited: a super-mitogenic insulin analogue.
Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D. Hansen BF, et al. Diabetologia. 2011 Sep;54(9):2226-31. doi: 10.1007/s00125-011-2203-8. Epub 2011 Jun 3. Diabetologia. 2011. PMID: 21633908 Review.
Hepatoselectivity and the evolution of insulin.
Herring R, Jones RH, Russell-Jones DL. Herring R, et al. Diabetes Obes Metab. 2014 Jan;16(1):1-8. doi: 10.1111/dom.12117. Epub 2013 May 16. Diabetes Obes Metab. 2014. PMID: 23679086 Review.
167 results